AEGiS-AP: Company Sold Dud Drug Associated PressImportant note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.
Click here to return to Associated Press main menu




DonateNow



Company Sold Dud Drug

The Associated Press - 5 Oct 1995


PHILADELPHIA (AP) -- Armour Pharmaceutical Co. kept a blood-clotting drug on the market in 1985, despite warnings its heat-treating process was not effective at killing the AIDS virus, according to a published report.

Two years later, six hemophiliacs in Vancouver, British Columbia, five of them children, contracted the AIDS virus from contaminated dosages of the drug, Factorate, The Philadelphia Inquirer reported today.

Several hemophiliacs in other parts of Canada, the United States and elsewhere also contracted the virus, the newspaper said.

Armour prevented virologist Alfred Prince from making his findings about Factorate public by invoking a confidentiality clause in his contract, according to an internal corporate document obtained by the Inquirer.

Telephone messages seeking comment from Collegeville-based Armour were not returned.

The report and other Armour documents held under seal in federal and Philadelphia courts were to be made public today by attorneys for a Canadian board of inquiry.

Armour, a subsidiary of what is now Rhone-Poulenc Rorer Inc., said in a recent Securities and Exchange Commission filing that it was a defendant in a total of 321 pending lawsuits brought by HIV-infected hemophiliacs or their survivors.

The U.S. Supreme Court on Monday denied an appeal by hemophiliacs to have their cases against Armour and other blood product manufacturers combined into a class action.

Armour withdrew Factorate from the Canadian market in November 1987 and from the United States a month later. It denied that the product was "unreasonably dangerous and defective."

Copyright 1995/The Associated Press. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, The Associated Press, 50 Rockefeller Plaza, New York, NY 10020.


951005
AP951006


Copyright © 1995 - Associated Press. Reproduction of this article (other than one copy for personal reference) must be cleared through the AP Permissions Desk.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, Pacific Life Foundation, and donations from users like you.

Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .